A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia
Status:
Completed
Trial end date:
2016-07-31
Target enrollment:
Participant gender:
Summary
This is a Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple
Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients with
Alzheimer's Disease Type Dementia.
Phase:
Phase 2
Details
Lead Sponsor:
Chase Pharmaceuticals Corporation Chase Pharmaceuticals Corporation, an affiliate of Allergan plc